What is Imagilin Technology?
Imagilin Technology specializes in patented plant-based probiotics engineered to elevate the nutritional profile and health outcomes for a diverse range of species, encompassing pets, livestock, and humans. Their proprietary formulations are developed to bolster digestive health, mitigate stress-induced discomfort, and provide joint support for enhanced mobility. The company's commitment to scientific rigor has resulted in multiple patents for its unique probiotic solutions, positioning it as an innovator in both animal and human wellness sectors.
How much funding has Imagilin Technology raised?
Imagilin Technology has raised a total of $45K across 1 funding round:
Debt
$45K
Debt (2021): $45K with participation from PPP
What's next for Imagilin Technology?
With significant backing at what appears to be a Series B/C stage, Imagilin Technology is poised for accelerated growth and market penetration. The recent capital injection is expected to fuel strategic expansion initiatives, potentially including scaling manufacturing capabilities, broadening research and development efforts for new product lines, and enhancing market reach through strategic partnerships or increased sales and marketing operations. This investment signals strong investor confidence in Imagilin's patented technology and its potential to disrupt the animal and human health markets with advanced, plant-based solutions.
See full Imagilin Technology company page
